Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men

International Journal of Obesity volume 27, pages 1494–1499 (2003)Cite this article

Abstract

OBJECTIVE: To examine the effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB protein) treatment in overweight men.

DESIGN: A randomized double-blind placebo-controlled trial in 24 overweight men (BMI: 28.8±0.3 kg/m2; age: 34.8±0.9 y). PEG-OB protein (80 mg) or placebo was administered subcutaneously weekly for 6 weeks, combined with a 2.1 MJ/day energy restriction program. Dietary restraint was determined by the Three-Factor Eating Questionnaire before and after treatment, and after 8 weeks follow-up.

RESULTS: During treatment dietary restraint increased, and general hunger, resting energy expenditure and respiratory quotient decreased similarly in the PEG-OB and the placebo group. With PEG-OB treatment, additional weight loss (P<0.03) was observed. During 8 weeks follow-up, body weight increase was larger in the PEG-OB group compared to placebo (P<0.05), and body weight regain was faster. Body weight regain was inversely correlated with the increase in cognitive dietary restraint during treatment (PEG-OB group: r2=0.49, P<0.02; placebo group: r2=0.60, P=0.01).

CONCLUSION: Although treatment with PEG-OB protein led to a greater body weight loss relative to placebo, weight maintenance thereafter was mainly supported by dietary restraint, which was more effective in the placebo-treated group, resulting in a slower regain of body weight.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Seidell JC . Dietary fat and obesity: an epidemiologic perspective. Am J Clin Nutr 1998; 67: 546S–550S.

    Article  CAS  Google Scholar 

  2. National Institutes of Health Consensus Developments Panel on the Health Implications of Obesity. Health implications of obesity. Ann Intern Med 1985; 103: 1073–1077.

  3. Lew E . Mortality and weight: insured lives and the American Cancer Society. Ann Intern Med 1985; 103: 1024–1029.

    Article  CAS  Google Scholar 

  4. Hubert H, Feinleid M, McNamara P, Casrelli WP . Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 986–977.

    Article  CAS  Google Scholar 

  5. Donahue R, Abbott RD, Bloom E, Reed DH, Yano K . Central obesity and coronary heart disease in men. Lancet 1987; 1: 821–824.

    Article  CAS  Google Scholar 

  6. Pasman WJ, Rössner S, Westerterp-Plantenga MS, Saris WHM . Body weight changes after treatment of obesity or pregnancy. In: Westerterp-Plantenga MS, Steffens A, Tremblay A (eds). Regulation of food intake. EDRA: Milan; 1999.

    Google Scholar 

  7. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res 1998; 6: 285–291.

    Article  CAS  Google Scholar 

  8. Muls E, Kempen K, Vansant G, Saris WHM . Is weight cycling detrimental to health? A review of the literature in humans. Int J Obes Relat Metab Disord 1995; 19(Suppl 3): S46–S50.

    PubMed  Google Scholar 

  9. Sjöstrom L, Rissanen A, Andersen T, Bolorin M, Golay A, Koppeschaar HP . Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–172.

    Article  Google Scholar 

  10. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM . Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.

    Article  CAS  Google Scholar 

  11. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P . The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. Horm Metab Res 1996; 28: 619–632.

    Article  CAS  Google Scholar 

  12. Campfield LA, Smith FJ, Burn P . OB protein: a hormonal controller of central neural network mediating behavioral, metabolic and neuro endocrine responses. Endocrinol Metab 1997; 4: 81–102.

    CAS  Google Scholar 

  13. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohanisesiian JP, Maarco CC, McKee LY, Bauer TL . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Eng J Med 1996; 334: 292–295.

    Article  CAS  Google Scholar 

  14. Pasman WJ, Westerterp-Plantenga MS, Saris WHM . The effect of exercise training on leptin levels in obese males. Am J Physiol 1998; 274: E280–E286.

    CAS  PubMed  Google Scholar 

  15. Heymsfield SB, Greenberg AS, Fujioka K, Didelimon RM, Kushner R, Hunt T, Lubina JA, Patanee J, Self B, Hunt P, McCahish H . Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled dose-escalation trial. JAMA 1999; 282: 1568–1575.

    Article  CAS  Google Scholar 

  16. Farooqi LS, Jebb S, Langmack G . Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Eng J Med 1999; 341: 879–884.

    Article  CAS  Google Scholar 

  17. Westerterp-Plantenga MS, Saris WHM, Hukshorn CJ, Campfield LA . Effects of weekly administration of pegylated recombinant human OB-protein on appetite profile and energy metabolism in obese men. Am J Clin Nutr 2001; 74: 426–434.

    Article  CAS  Google Scholar 

  18. Stunkard AJ, Messick S . The Three Factor Eating Questionnaire to measure dietary restraint, disinhibition and hunger. Psychol Res 1985; 29:71–83.

    CAS  Google Scholar 

  19. Pasman WJ, Saris WHM, Westerterp-Plantenga MS . Predictors of weight maintenance. Obes Res 1999; 7: 43–50.

    Article  CAS  Google Scholar 

  20. Westerterp-Plantenga MS, Kempen KP, Saris WHM . Determinants of weight maintenance in women after diet-induced weight reduction. Int J Obes Relat Metab Disord 1998; 22: 1–6.

    Article  CAS  Google Scholar 

  21. Pekkarinen T, Takala I, Mustajoki P . Two year maintenance of weight loss after a VLCD and behavioral therapy for obesity: correlation to the scores of questionnaires measuring eating behavior. Int J Obes Relat Metab Disord 1996; 20: 332–337.

    CAS  PubMed  Google Scholar 

  22. Clark MM, Marcus BH, Pera V, Niaura RS . Changes in eating inventory scores following obesity treatment. Int J Eat Disord 1994; 15:401–405.

    Article  CAS  Google Scholar 

  23. Lejeune MPGM, Van Aggel DCP, Van Baak MA, Westerterp-Plantenga MS . Dietary restraint during weight maintenance with or without exercise training, in men. Eur J Clin Nutr (in press).

  24. d'Amore A, Massignan C, Montera P, Moles A, De Lorenzo A, Scucchi S . Relationship between dietary restraint, binge eating, and leptin in obese women. Int J Obes Relat Metab Disord 2001; 25: 373–377.

    Article  CAS  Google Scholar 

  25. Von Prittwitz S, Blum WF, Ziegler A, Scharmann S, Remschmidt H, Hebebrand J . Restrained eating, measured with the TFEQ is associated with low leptin levels in underweight females. Mol Psychiatry 1997; 2: 420–422.

    Article  CAS  Google Scholar 

  26. Westerterp-Plantenga MS, Rolland V, Wilson SA, Westerterp KR . Satiety related to 24 h diet-induced thermogenesis during high protein/carbohydrate vs high fat diets measured in a respiration chamber. Eur J Clin Nutr 1999; 53: 495–502.

    Article  CAS  Google Scholar 

  27. Nucci ML, Shor R, Abuchoweski A . The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Delivery Rev 1991; 6: 133–151.

    Article  CAS  Google Scholar 

  28. Fuertges F, Abuchoweski A . The clinical efficacy of poly(ethylene glycol)-modified proteins. J Controlled Rel 1990; 11: 139–148.

    Article  CAS  Google Scholar 

  29. Campfield LA, Devos R, Guisez Y . Pegylated obese (OB) protein compositions. US Patent Number 6,025,324, 2/15/2000.

  30. Bailon P, Campfield LA, Devos R . Pegylated obese (OB) protein compositions. US Patent Number 6,025,325, 2/15/2000.

  31. Westerterp KR, Wouters L, Van Marken Lichtenbelt WD . The Maastricht protocol for the measurement of body composition and energy expenditure with labeled water. Obes Res 1995; 3(Suppl 1): 49–57.

    Article  Google Scholar 

  32. Siri WE . The gross composition of the body. Adv Biol Med Physiol 1956; 4: 239–280.

    Article  CAS  Google Scholar 

  33. Hukshorn CJ, Saris WHM, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA . Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–4009.

    Article  CAS  Google Scholar 

  34. Schoffelen PFM, Westerterp KR, Saris WHM, Ten Hoor F . A dual respiration chamber with automated calibration. J Appl Physiol 1997; 83: 2064–2072.

    Article  CAS  Google Scholar 

  35. Weir JBDV . New methods for calculating metabolic rate with special references to protein metabolism. J Physiol 1949; 109: 1–9.

    Article  Google Scholar 

  36. Hukshorn CJ, Westerterp-Plantenga MS, Saris WHM . Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severly energy-restricted, overweight men. Am J Clin Nutr 2003; 77: 771–776.

    Article  CAS  Google Scholar 

  37. Kahler A, Geary N, Eckel LA, Campfield LA, Smith FJ, Langhans W . Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rat. Am J Physiol 1998; 275: R180–R185.

    CAS  PubMed  Google Scholar 

  38. Eckel LA, Langhans W, Kahler A, Campfield LA, Smith FJ, Geary N . Chronic administration of OB protein decreases food intake by selectively reducing meal size in female rat. Am J Physiol 1998; 275: R186–R193.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Biology, Maastricht University, Maastricht, The Netherlands

    M P G M Lejeune, C J Hukshorn, W H M Saris & M S Westerterp-Plantenga

Authors
  1. M P G M Lejeune
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C J Hukshorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W H M Saris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M S Westerterp-Plantenga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M P G M Lejeune.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lejeune, M., Hukshorn, C., Saris, W. et al. Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men. Int J Obes 27, 1494–1499 (2003). https://doi.org/10.1038/sj.ijo.0802431

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802431

Keywords

This article is cited by

Search

Advanced search

Quick links